Purpose: To investigate microvascular changes in the macular and peripapillary area in prolactinoma patients by using optical coherence tomography angiography (OCTA).
Design: A retrospective study.
Methods: This study included 40 patients with treatment-naive prolactinoma and 42 healthy controls. Participants underwent comprehensive ophthalmic examinations, visual field testing, and optical coherence tomography (OCT) assessments, including retinal nerve fiber layer (RNFL) thickness, macular, and peripapillary region OCTA by using the Topcon DRI OCT Triton Swept Source-OCT system. The OCTA results were evaluated between groups and then correlated with PRL levels.
Results: The differences in best-corrected visual acuities were statistically significant among the groups. The RNFL thickness in the superior and nasal quadrants was significantly lower in the prolactinoma group. The prolactinoma group showed significant reductions in macular vessel density (VD) across all layers than the control group, except in the deep retinal capillary plexus temporal quadrants. The radial peripapillary capillary (RPC) temporal VD in the prolactinoma group was significantly lower. In patients with optic neuropathy, correlations were observed between the RPC temporal and RNFL temporal sectors (r = 0.650, P = 0.03), and between the RPC inferior and RNFL inferior sectors (r = -0.612, P = 0.045). Between PRL levels and OCTA parameters, negative correlations were observed (RPC inferior: r = -0.452, P = 0.003; DCP superior: r = -0.379, P = 0.016).
Conclusion: Our study revealed reduced VD in the macula and RPC temporal regions in patients with treatment-naive prolactinoma. OCTA holds significant importance in detecting potential retinopathies and vasculopathies. Future research should focus on examining pre- and post-treatment changes in treatment-naive patients without ON to better understand the impact of prolactinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/IJO.IJO_1301_24 | DOI Listing |
J Med Case Rep
December 2024
Department of Neurosurgery, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Background: Giant prolactinoma (size > 4 cm) is a rare condition and accounts for less than 1% of pituitary adenomas. In even rarer cases, these lesions may involve craniocervical structures requiring surgical intervention. The present case is the largest reported giant prolactinoma (99 × 72 × 57 mm).
View Article and Find Full Text PDFJ Tradit Chin Med
December 2024
Laboratory Department, Wuhan Center for Clinical Laboratory, Wuhan 430015, China.
Cureus
October 2024
Department of Endocrinology, Metabolism and Diabetes, Health Sciences University, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, TUR.
Pituitary
December 2024
Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Via Olgettina 60, Milan, 20132, Italy.
Prolactinomas account for more than half of pituitary adenomas, and besides their clinical impact on fertility and gonadal function, they lead to detrimental effects on bone. Patients with prolactinoma are prone to deterioration of bone structure caused not only by prolactin (PRL) induced hypogonadism but also by its direct actions on bone cells and calcium metabolism. However, clinical studies have shown inconsistent evidence regarding whether PRL could have a deleterious effect independently from gonadal insufficiency on skeletal integrity.
View Article and Find Full Text PDFEndocrinology
October 2024
Laboratorio de Fisiopatología Hormonal, IBYME-CONICET, C1428ADN Buenos Aires, Argentina.
Prolactinomas, the most common pituitary-secreting adenomas, can be effectively treated with dopamine D2 receptor (D2R) agonists. However, a subset of them (∼20%) are resistant to dopamine-based therapies and require extirpation. The molecular mechanisms underlying their escape from dopaminergic regulation are not fully elucidated and may include alterations in D2R signaling.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!